Gastric Telangiectasias in Chronic Hemodialysis Patients: A Report of Six Cases

Cunningham, J. T.

doi:10.1016/s0016-5085(81)80023-6

Cited by 55 publications

(8 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The diagnosis of GAVE is achieved on the basis of endoscopic and histological appearance. The etiology of GAVE remains unknown, and it is thought to encompass a variety of conditions including autoimmune disease, liver cirrhosis, portal hypertension, chronic renal failure, cardiovascular disease, achlorhydria, severe hypochlorhydria, hypothyroidism, and diabetes mellitus 10–15 . In Gostout's article, atrophic gastritis occurred in 19 of 19 (100%) biopsies, and hypergastrinemia was observed in 25 of 33 (76%) patients tested 16 .…”

Section: Discussionmentioning

confidence: 99%

Endoscopic band ligation versus argon plasma coagulation for gastric antral vascular ectasia associated with liver diseases

Sato

Yamazaki

Akaike

2011

Digestive Endoscopy

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Endoscopic band ligation versus argon plasma coagulation for gastric antral vascular ectasia associated with liver diseases

Sato

Yamazaki

Akaike

2011

Digestive Endoscopy

View full text Add to dashboard Cite

show abstract

“…In dialysis patients, there is no information available about the usefulness of colon-cancer screening. Screening efforts based on stool-guaiac testing might be com- (6,7). In hemodialysis patients, daily occult blood losses of -5 ml have been demonstrated by radioisotopic labeling (8).…”

Section: Discussionmentioning

confidence: 99%

Colon‐Cancer Screening in Dialysis Patients

et al. 1990

View full text Add to dashboard Cite

The usefulness of colon‐cancer screening using stool‐guaiac testing has been established in large control populations, but not in dialysis patients. In 72 asymptomatic dialysis patients [51 treated with hemodialysis (HD), and 21 with peritoneal dialysis (PD)] who underwent outpatient stool occult blood testing, the test result was positive in 11 (15%) patients (8 HD and 3 PD). Eight of the 11 were investigated further by colonoscopy and, when deemed necessary by the treating physician, esophago‐gastroduodenoscopy and/or barium enema were also performed. A site of active bleeding was identified in three of the eight patients (hemorrhoids, telangiectasia, ulcerative colitis). In each of the five other patients, potentially bleeding lesions were identified: colonic polyps (two malignant and two benign) in four patients, Barrett's esophagus in one, diverticulosis in two, and colonic vascular deformities in two. These results were compared with those of a large ongoing fecal occult blood screening program in which the prevalence of positive stool occult blood tests is 5% and in which 42% of the positive patients have colonic neoplasms. Thus, although the baseline incidence of positive guaiac tests may be higher in dialysis patients than in nonuremic controls, our results suggest that stool guaiac testing of dialysis patients may not only be useful in detecting colonic polyps, but may also identify other previously unsuspected causes of gastrointestinal bleeding.

show abstract

“…A further use of conjugated estrogen has been in the treatment of gastrointestinal telangiectasias in chronic renal failure. Several reports suggest that hemodialysis patients are predisposed to developing gastrointestinal telangiectasias which are felt to be responsible for more than 20% of initial episodes of gastrointestinal hemorrhage and 50% of episodes of recurrent bleeding (85,9). Standard therapy has included electrocoagulation, laser therapy and surgical resection.…”

Section: Conjugated Estrogensmentioning

confidence: 99%